Tesamorelin – Stabilised GHRH Analogue for Research

Tesamorelin is an advanced synthetic analogue of human growth hormone-releasing hormone, also known as GHRH or growth hormone-releasing factor. It contains the complete 44-amino-acid sequence of human GRF with a specialised N-terminal trans-3-hexenoyl modification. This molecular modification supports improved resistance to rapid enzymatic degradation and gives Tesamorelin a more stable research profile than naturally occurring GHRH. Its clearly defined structure makes Tesamorelin particularly relevant for professional laboratory studies involving GHRH receptor activity, pituitary signalling, endogenous growth hormone release, the GH–IGF-1 axis and stabilised peptide development. Tesamorelin is supplied as a premium lyophilised research material in a securely sealed vial with clear batch information, professional packaging and fast order processing from Peptides Divas.

Viktiga produktfunktioner

• Synthetic human GHRH analogue
• Complete 44-amino-acid peptide sequence
• Also known by the research designation TH9507
• Specialised N-terminal hexenoyl modification
• Designed for improved molecular stability
• Relevant for GHRH receptor research
• Suitable for pituitary signalling studies
• Useful for GH and IGF-1 pathway research
• Levereras som frystorkat forskningsmaterial
• Tydlig batchspecifik produktinformation
• Säker och diskret förpackning
• Snabb och spårbar leverans i Europa

What Is Tesamorelin?

Tesamorelin is a synthetic peptide based on the complete amino-acid sequence of naturally occurring human growth hormone-releasing hormone. Natural GHRH is produced in the hypothalamus and communicates with specialised receptors located on somatotroph cells within the anterior pituitary. This signalling system is involved in regulating the synthesis and pulsatile release of endogenous growth hormone. Naturally occurring GHRH is rapidly broken down by enzymes. Tesamorelin contains an N-terminal trans-3-hexenoyl group attached to its tyrosine residue, creating a stabilised GHRH analogue suitable for extended peptide and receptor research.

Molekylstruktur

Tesamorelin contains 44 amino acids and retains the complete sequence of human GRF. Its structural characteristics include:

• Complete human GRF 1–44 sequence
• N-terminal tyrosine residue
• Trans-3-hexenoyl molecular modification
• C6 carbon chain containing a double bond
• Stabilised synthetic peptide structure
• GHRH receptor agonist activity
• Approximate molecular weight of 5.1 kDa
• Commonly prepared and analysed as an acetate salt

The hexenoyl modification differentiates Tesamorelin from unmodified human GHRH and shorter GHRH fragments.

GHRH-receptorforskning

Tesamorelin is primarily studied in relation to the growth hormone-releasing hormone receptor. The GHRH receptor is a G-protein-coupled receptor expressed mainly on pituitary somatotroph cells. Activation of this receptor initiates intracellular signalling associated with growth hormone synthesis and secretion. Potential areas of laboratory research include:

• GHRH-receptorbindning
• Receptoraktivering
• Ligand-receptorinteraktioner
• Cyklisk AMP-signalering
• Intracellular calcium pathways
• Pituitary somatotroph activity
• Receptorinternalisering
• Receptorkänslighet
• Koncentration-responsförhållanden
• Comparative GHRH analogue pharmacology

The exact experimental conditions and analytical methods should be established by the qualified laboratory conducting the research.

Pituitary Signalling Research

The anterior pituitary is an important endocrine signalling centre responsible for releasing several protein and peptide hormones. Tesamorelin may be relevant for controlled laboratory studies involving:

• Somatotroph-cell signalling
• Endogenous growth hormone release
• Pulsatile hormone secretion
• Pituitary receptor expression
• Intracellulär signaltransduktion
• Hormone-release kinetics
• Hypothalamic–pituitary communication
• Endokrina återkopplingsmekanismer
• Comparative pituitary-cell assays
• GHRH-mediated cellular responses

Tesamorelin stimulates the GHRH pathway rather than acting as recombinant growth hormone itself.

GH–IGF-1 Axis Research

The growth hormone and insulin-like growth factor 1 axis forms an interconnected endocrine signalling network. GHRH receptor activation in the pituitary can influence endogenous growth hormone secretion. Growth hormone subsequently participates in signalling associated with IGF-1 production and broader endocrine feedback systems. Tesamorelin may therefore be studied in relation to:

• Growth hormone pulsatility
• GH secretion patterns
• IGF-1-associated signalling
• Endokrina återkopplingsslingor
• Hypothalamic–pituitary communication
• Analys av hormonbiomarkörer
• Metabolic signalling pathways
• Protein-turnover mechanisms
• Jämförande endokrina modeller
• Time-dependent hormone responses

These pathways describe areas of scientific interest and should not be interpreted as guaranteed effects from a non-pharmaceutical research material.

Stabilised Peptide Research

The N-terminal hexenoyl modification makes Tesamorelin particularly relevant for research into peptide stabilisation and molecular engineering. Potential research topics include:

• Resistance to enzymatic degradation
• N-terminal peptide modification
• Molekylär halveringstidsförlängning
• Peptide clearance
• Struktur-aktivitetsförhållanden
• Long-acting peptide design
• Peptide pharmacokinetics
• Modified GHRH analogues
• Molekylär stabilitet
• Peptide formulation development

Researchers may compare Tesamorelin with native GHRH, sermorelin, Modified GRF 1–29 or other GHRH-related compounds.

Tesamorelin Versus Sermorelin

Tesamorelin and sermorelin are both related to human GHRH, but they are not identical compounds.

Karakteristisk	Tesamorelin
Peptidsekvens	Human GRF 1–44
Peptidlängd	44 amino acids
Molekylär modifiering	N-terminal trans-3-hexenoyl group
Primary receptor	GHRH-receptor
Forskningsprofil	Stabilised full-length GHRH analogue
Alternativ beteckning	TH9507

Sermorelin generally refers to the shorter GHRH 1–29 sequence and does not contain the same hexenoyl modification.

Tesamorelin Versus CJC-1295

Tesamorelin and CJC-1295 are both synthetic GHRH-related peptides, but their structures and stabilisation strategies differ. Tesamorelin contains the full 44-amino-acid human GRF sequence with an N-terminal hexenoyl modification. CJC-1295 with DAC uses a different modified peptide sequence and an albumin-binding Drug Affinity Complex. Researchers should not treat these compounds as interchangeable and should verify the exact product identity through batch-specific analytical documentation.

Forskning om metabola vägar

The GH–IGF-1 axis interacts with multiple metabolic and endocrine systems. Tesamorelin may be relevant for laboratory models involving:

• Lipidrelaterad signalering
• Glukos-homeostasvägar
• Protein metabolism
• Hepatic signalling
• Adipocyte biology
• Endocrine–metabolic communication
• Cellulär energireglering
• Hormone-responsive gene expression
• Analys av metabolisk biomarkör
• Jämförande peptidforskning

Research results can vary according to the biological model, concentration, exposure duration and analytical method.

Potentiella forskningsapplikationer

Tesamorelin may be suitable for controlled scientific research involving:

• GHRH receptor pharmacology
• Pituitary somatotroph signalling
• Endogenous growth hormone secretion
• Growth hormone pulsatility
• GH–IGF-1 axis research
• Hypothalamic–pituitary communication
• Endokrina återkopplingsmekanismer
• Peptide stabilisation
• N-terminal molecular modification
• Struktur-aktivitetsförhållanden
• Metabolisk signalering
• Analytisk peptidkarakterisering
• Kromatografisk analys
• Masspektrometrianalys
• Stabilitets- och nedbrytningstestning
• Comparative GHRH analogue research

The receiving laboratory is responsible for determining and validating appropriate concentrations, controls and analytical procedures.

Analytisk forskning

Tesamorelin may be suitable for professional analytical applications involving:

• Högpresterande vätskekromatografi
• Vätskekromatografi – masspektrometri
• Bekräftelse av peptididentitet
• Molekylviktsanalys
• Verifiering av aminosyrasekvens
• Renhetsbedömning
• Stabilitetstestning
• Nedbrytningsprofilering
• Löslighetsbedömning
• Jämförelse av referensmaterial
• Formuleringskompatibilitet
• Analytisk metodutveckling

Because Tesamorelin contains an N-terminal lipid modification, analytical methods should be validated specifically for this compound.

Produktspecifikationer

Produktegenskaper	Information
Produktnamn	Tesamorelin
Alternativ beteckning	TH9507
Produktkategori	Syntetisk forskningspeptid
Förenad typ	Stabilised GHRH analogue
Peptidlängd	44 amino acids
Strukturell grund	Complete human GRF 1–44 sequence
Molekylär modifiering	N-terminal trans-3-hexenoyl group
Primärt forskningsmål	GHRH-receptor
Huvudsaklig forskningsväg	Tillväxthormon och IGF-1-axeln
Approximate molecular weight	5.1 kDa
Form	Frystorkat forskningsmaterial
Presentation	Säkert förseglad forskningsflaska
Dokumentation	Batchspecifik analytisk information
Förpackning	Säker och diskret förpackning
Avsedd tillämpning	Vetenskaplig, analytisk och laboratorieforskning

Frystorkat forskningsformat

Tesamorelin is supplied as a lyophilised research material in a securely sealed vial. Lyophilisation removes moisture and helps support peptide stability during controlled storage and transportation. Minor differences in physical appearance may occur because of product quantity, production conditions and residual moisture. Physical appearance alone should not be used to establish product identity, purity or analytical quality. Researchers should review the documentation associated with the applicable batch before beginning laboratory work.

Kvalitet och produkttransparens

Peptides Divas focuses on clearly displayed product specifications, professional handling and batch-level traceability. Available analytical information may include:

• Produktidentifiering
• Peptidsekvens
• Batch- eller lotnummer
• Rapporterad renhet
• HPLC-analys
• Masspektrometridata
• Information om molekylvikt
• Testinformation
• Produktens utseende
• Förvaringsrekommendationer

Detta ger forskare tydlig och spårbar information för den aktuella produktbatchen.

Lagringsinformation

Store Tesamorelin in its original sealed packaging according to the conditions displayed on the product label and applicable batch documentation. Protect the research material from:

• Direkt solljus
• Överdriven värme
• Fukt
• Förorening
• Skadad förpackning
• Upprepade temperaturfluktuationer
• Onödig exponering för luft

Det mottagande laboratoriet ansvarar för att fastställa lämpliga rutiner för förberedelse, hantering och förvaring för sitt specifika forskningsprotokoll.

Why Choose Tesamorelin?

Tesamorelin provides a clearly defined and stabilised full-length GHRH analogue for advanced receptor and endocrine research. Key research advantages include:

• Complete 44-amino-acid human GRF sequence
• Specialised N-terminal hexenoyl modification
• Relevant för studier av GHRH-receptorer
• Suitable for pituitary signalling research
• Useful for GH–IGF-1 axis models
• Valuable for peptide-stability analysis
• Suitable for comparative GHRH research
• Praktisk frystorkad presentation
• Tydlig batchspecifik produktinformation

Varför beställa från Peptides Divas?

Peptides Divas kombinerar noggrant utvalda forskningsmaterial med snabb, pålitlig och professionell service. Kunderna drar nytta av:

• Tydligt visade produktspecifikationer
• Batchspecifik analytisk information
• Snabb orderhantering
• Säker och diskret förpackning
• Spårbara fraktalternativ
• Noggrant skydd av flaskorna
• Responsiv kundsupport
• Pålitlig europeisk leverans

Choose Tesamorelin from Peptides Divas for advanced laboratory research involving GHRH receptor activity, pituitary signalling, the GH–IGF-1 axis and stabilised peptide design. For laboratory research use only. Not intended for human or veterinary use.